Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 11/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13431124 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL30571418 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL12897943 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL18269413 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL3221050 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL13625375 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL14669553 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL245091 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL30571404 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL13764732 | 1.00 | HMGCR (0.74) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434067-B2 | Composite formulation for oral administration comprising ezetimibe and rosuvastatin | HANMI PHARM. CO., LTD. (KR) | 2019-10-08 | — | — | US | claimed |
| US-20160346213-A1 | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN | HANMI PHARM. CO., LTD. (KR) | 2016-12-01 | — | — | US | claimed |
| EP-3089739-A1 | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN | Hanmi Pharm. Co., Ltd. (KR) | 2016-11-09 | — | — | EP | claimed |
| WO-2015102400-A1 | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN | HANMI PHARM. CO., LTD. (KR) | 2015-07-09 | — | — | WO | claimed |
| US-10434067-B2 | Composite formulation for oral administration comprising ezetimibe and rosuvastatin | HANMI PHARM. CO., LTD. (KR) | 2019-10-08 | — | — | US | disclosed |
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2019-02-07 | — | — | US | disclosed |
| EP-2513065-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2018-10-17 | — | — | EP | disclosed |
| US-20160346213-A1 | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN | HANMI PHARM. CO., LTD. (KR) | 2016-12-01 | — | — | US | disclosed |
| EP-3089739-A1 | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN | Hanmi Pharm. Co., Ltd. (KR) | 2016-11-09 | — | — | EP | disclosed |
| US-9371291-B2 | Process for the manufacture of the calcium salt of rosuvastatin (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-enoic acid and crystalline intermediates thereof | ASTRAZENECA UK LIMITED (GB) | 2016-06-21 | — | — | US | disclosed |
| US-9126975-B2 | Process for the preparation of statins in the presence of base | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2015-09-08 | — | — | US | disclosed |
| EP-2665723-B1 | PROCESS FOR THE PREPARATION OF STATINS IN THE PRESENCE OF BASE | DSM SINOCHEM PHARM NL BV (NL) | 2015-07-22 | — | — | EP | disclosed |
| US-20110301348-A1 | Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-[4-(4-Fluorophenyl)-6-Isopropyl-2-[Methyl(Methylsulfonyl)Amino]-Pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof | ASTRAZENECA UK LIMITED (GB) | 2011-12-08 | — | — | US | disclosed |
| WO-2011073232-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073232-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2011-06-23 | — | — | WO | disclosed |
| EP-2336116-A1 | Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof | LEK Pharmaceuticals d.d. (SI) | 2011-06-22 | — | — | EP | disclosed |
| EP-2336116-A1 | Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof | LEK Pharmaceuticals d.d. (SI) | 2011-06-22 | — | — | EP | disclosed |
| EP-2272842-A1 | Process for the manufacture of the calcium salt of rosuvastatin and crystalline intermediates thereof | AstraZeneca UK Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| WO-2010077062-A2 | PREPARATION METHOD OF STATIN COMPOUND AND BENZOTHIAZOLYL SULFONE COMPOUND USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2010-07-08 | — | — | WO | disclosed |
| US-20070255060-A1 | Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-'4-(4-Fluorophenyl)-6-Isopropyl-2-'Methyl (Methylsulfonyl) Amino ! Pyrmidin -5-Yl! (3R, 5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof | ASTRAZENECA UK LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | FABP3, TNNI3, TNNT2 | HMGCR 18/4885 |
| US-20110301348-A1 | Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-[4-(4-Fluorophenyl)-6-Isopropyl-2-[Methyl(Methylsulfonyl)Amino]-Pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof | HMGCR, DHCR7, GRHPR | HMGCR 1/4885 |
| US-20070255060-A1 | Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-'4-(4-Fluorophenyl)-6-Isopropyl-2-'Methyl (Methylsulfonyl) Amino ! Pyrmidin -5-Yl! (3R, 5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof | HMGCR, DHCR7, FADS2 | HMGCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.